 Bennett Chin
Concepts (300)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiopharmaceuticals | 26 | 2022 | 205 | 3.140 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 19 | 2014 | 104 | 2.130 |
Why?
| | Neuroendocrine Tumors | 3 | 2024 | 119 | 1.530 |
Why?
| | Fluorodeoxyglucose F18 | 15 | 2019 | 161 | 1.490 |
Why?
| | Iodine Radioisotopes | 8 | 2023 | 136 | 1.290 |
Why?
| | Organometallic Compounds | 6 | 2023 | 113 | 1.250 |
Why?
| | Positron-Emission Tomography | 8 | 2024 | 343 | 1.020 |
Why?
| | Tomography, Emission-Computed | 9 | 2004 | 71 | 1.010 |
Why?
| | Radionuclide Imaging | 14 | 2023 | 115 | 0.710 |
Why?
| | Image Enhancement | 4 | 2007 | 200 | 0.680 |
Why?
| | Positron Emission Tomography Computed Tomography | 6 | 2025 | 117 | 0.680 |
Why?
| | Heart | 8 | 2014 | 626 | 0.620 |
Why?
| | 3-Iodobenzylguanidine | 3 | 2023 | 13 | 0.600 |
Why?
| | Fluorine Radioisotopes | 3 | 2017 | 14 | 0.580 |
Why?
| | Prostatic Neoplasms | 5 | 2025 | 978 | 0.580 |
Why?
| | Thallium Radioisotopes | 5 | 1999 | 8 | 0.530 |
Why?
| | Phantoms, Imaging | 8 | 2025 | 159 | 0.500 |
Why?
| | Urinary Retention | 1 | 2016 | 24 | 0.480 |
Why?
| | Carcinosarcoma | 1 | 2016 | 23 | 0.480 |
Why?
| | Leucine | 1 | 2017 | 116 | 0.480 |
Why?
| | Contrast Media | 6 | 2014 | 497 | 0.480 |
Why?
| | Paraganglioma | 3 | 2023 | 64 | 0.470 |
Why?
| | Oxyquinoline | 2 | 2007 | 3 | 0.460 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 102 | 0.440 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 641 | 0.410 |
Why?
| | Whole Body Imaging | 2 | 2014 | 29 | 0.400 |
Why?
| | Gated Blood-Pool Imaging | 2 | 2007 | 6 | 0.400 |
Why?
| | Leukemia L1210 | 2 | 2012 | 7 | 0.400 |
Why?
| | Gallium Radioisotopes | 2 | 2023 | 16 | 0.390 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.350 |
Why?
| | Chloroquine | 1 | 2012 | 54 | 0.350 |
Why?
| | Technetium Tc 99m Sestamibi | 8 | 2016 | 13 | 0.340 |
Why?
| | Isoenzymes | 1 | 2012 | 294 | 0.330 |
Why?
| | Phenylalanine | 1 | 2011 | 69 | 0.330 |
Why?
| | Myocardial Infarction | 3 | 2007 | 1210 | 0.320 |
Why?
| | Thyroid Neoplasms | 3 | 2016 | 350 | 0.320 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2023 | 98 | 0.310 |
Why?
| | Pheochromocytoma | 2 | 2023 | 67 | 0.310 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2007 | 394 | 0.300 |
Why?
| | Coronary Circulation | 5 | 2002 | 134 | 0.300 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2009 | 99 | 0.290 |
Why?
| | Electrocardiography | 2 | 2014 | 665 | 0.290 |
Why?
| | Tissue Distribution | 3 | 2017 | 335 | 0.280 |
Why?
| | Aldehydes | 1 | 2009 | 139 | 0.280 |
Why?
| | Sensitivity and Specificity | 7 | 2017 | 1997 | 0.270 |
Why?
| | Radiation Dosage | 3 | 2015 | 193 | 0.270 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2382 | 0.250 |
Why?
| | Lung Neoplasms | 3 | 2016 | 2664 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 7 | 2008 | 2769 | 0.240 |
Why?
| | Image Interpretation, Computer-Assisted | 2 | 2005 | 288 | 0.230 |
Why?
| | Gamma Cameras | 1 | 2005 | 6 | 0.230 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 298 | 0.230 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 321 | 0.220 |
Why?
| | Radiometry | 2 | 2017 | 56 | 0.220 |
Why?
| | Urea | 1 | 2025 | 85 | 0.220 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2006 | 73 | 0.220 |
Why?
| | Humans | 48 | 2025 | 145474 | 0.220 |
Why?
| | Intercostal Muscles | 1 | 2004 | 4 | 0.220 |
Why?
| | Indium Radioisotopes | 3 | 1999 | 12 | 0.210 |
Why?
| | Feasibility Studies | 6 | 2009 | 1111 | 0.210 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2004 | 1149 | 0.210 |
Why?
| | Somatostatin | 3 | 2016 | 53 | 0.200 |
Why?
| | Data Curation | 1 | 2024 | 21 | 0.200 |
Why?
| | Stomach Neoplasms | 2 | 2022 | 128 | 0.200 |
Why?
| | Vocal Cord Paralysis | 1 | 2003 | 27 | 0.200 |
Why?
| | Vocal Cords | 1 | 2003 | 27 | 0.200 |
Why?
| | Digestive System Neoplasms | 1 | 2003 | 9 | 0.200 |
Why?
| | Thyrotropin | 1 | 2004 | 120 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 9 | 2025 | 3904 | 0.190 |
Why?
| | Lysine | 1 | 2025 | 305 | 0.190 |
Why?
| | Carcinoma, Papillary | 1 | 2003 | 77 | 0.190 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2003 | 59 | 0.190 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2002 | 19 | 0.190 |
Why?
| | Atherosclerosis | 1 | 2007 | 409 | 0.190 |
Why?
| | Myocardial Contraction | 2 | 2002 | 293 | 0.190 |
Why?
| | Lutetium | 1 | 2022 | 5 | 0.190 |
Why?
| | Image Processing, Computer-Assisted | 5 | 2025 | 779 | 0.180 |
Why?
| | Myocardial Stunning | 1 | 2002 | 4 | 0.180 |
Why?
| | Receptors, Peptide | 1 | 2022 | 18 | 0.180 |
Why?
| | Paraganglioma, Extra-Adrenal | 1 | 2022 | 9 | 0.180 |
Why?
| | Dobutamine | 1 | 2002 | 24 | 0.180 |
Why?
| | Radioisotopes | 1 | 2022 | 37 | 0.180 |
Why?
| | Intestinal Neoplasms | 1 | 2022 | 30 | 0.180 |
Why?
| | Animals | 19 | 2025 | 38030 | 0.180 |
Why?
| | Cell Line, Tumor | 3 | 2017 | 3542 | 0.170 |
Why?
| | Diabetic Nephropathies | 1 | 2024 | 322 | 0.160 |
Why?
| | Artificial Intelligence | 1 | 2025 | 381 | 0.160 |
Why?
| | Oxygen Consumption | 1 | 2003 | 718 | 0.150 |
Why?
| | Mice | 8 | 2019 | 18329 | 0.150 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 2 | 1999 | 6 | 0.150 |
Why?
| | Male | 28 | 2025 | 72842 | 0.150 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 1999 | 38 | 0.150 |
Why?
| | Female | 29 | 2025 | 78844 | 0.150 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 1999 | 11 | 0.150 |
Why?
| | Stem Cells | 1 | 2003 | 628 | 0.140 |
Why?
| | Receptors, Somatostatin | 1 | 1999 | 24 | 0.140 |
Why?
| | Hormone Antagonists | 1 | 1999 | 33 | 0.140 |
Why?
| | Thymoma | 1 | 1999 | 37 | 0.140 |
Why?
| | Thymus Neoplasms | 1 | 1999 | 30 | 0.140 |
Why?
| | Radiation Pneumonitis | 1 | 1999 | 31 | 0.140 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1999 | 130 | 0.140 |
Why?
| | Metal Nanoparticles | 1 | 2019 | 80 | 0.140 |
Why?
| | Middle Aged | 20 | 2025 | 36215 | 0.140 |
Why?
| | Sodium Pertechnetate Tc 99m | 1 | 1997 | 4 | 0.140 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 1998 | 95 | 0.130 |
Why?
| | Coronary Disease | 2 | 2000 | 381 | 0.130 |
Why?
| | Dipyridamole | 2 | 2002 | 28 | 0.130 |
Why?
| | Myocardium | 1 | 2003 | 934 | 0.130 |
Why?
| | Frontal Lobe | 1 | 1998 | 160 | 0.130 |
Why?
| | Isotope Labeling | 2 | 2011 | 82 | 0.130 |
Why?
| | Hematoma | 1 | 1997 | 63 | 0.130 |
Why?
| | Smoking | 1 | 2004 | 1472 | 0.130 |
Why?
| | Cardiac Surgical Procedures | 1 | 2003 | 610 | 0.130 |
Why?
| | Pancreatic Neoplasms | 2 | 2022 | 928 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 561 | 0.120 |
Why?
| | Transurethral Resection of Prostate | 1 | 2016 | 2 | 0.120 |
Why?
| | Safety | 1 | 2018 | 358 | 0.120 |
Why?
| | Brain Neoplasms | 2 | 2019 | 1329 | 0.120 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 337 | 0.120 |
Why?
| | Neoplasms | 1 | 2012 | 2906 | 0.120 |
Why?
| | Vasodilator Agents | 2 | 2002 | 330 | 0.110 |
Why?
| | Parathyroid Diseases | 1 | 2015 | 2 | 0.110 |
Why?
| | Molecular Structure | 1 | 2017 | 486 | 0.110 |
Why?
| | Thyroid Nodule | 1 | 2016 | 57 | 0.110 |
Why?
| | Four-Dimensional Computed Tomography | 1 | 2015 | 38 | 0.110 |
Why?
| | Sarcoidosis | 1 | 1997 | 163 | 0.110 |
Why?
| | Androstenes | 1 | 2015 | 16 | 0.110 |
Why?
| | Phenylthiohydantoin | 1 | 2015 | 44 | 0.110 |
Why?
| | Stroke Volume | 2 | 1997 | 654 | 0.110 |
Why?
| | Ventricular Function, Right | 1 | 1997 | 297 | 0.110 |
Why?
| | Taxoids | 1 | 2015 | 114 | 0.110 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2015 | 100 | 0.110 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2015 | 53 | 0.100 |
Why?
| | Mediastinum | 1 | 2014 | 23 | 0.100 |
Why?
| | Dementia | 1 | 1998 | 327 | 0.100 |
Why?
| | Dogs | 4 | 2003 | 458 | 0.100 |
Why?
| | Mice, Inbred BALB C | 1 | 2017 | 1261 | 0.100 |
Why?
| | Prednisone | 1 | 2015 | 224 | 0.100 |
Why?
| | Coronary Stenosis | 3 | 2002 | 40 | 0.100 |
Why?
| | Ventricular Function, Left | 1 | 1997 | 542 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 1997 | 335 | 0.100 |
Why?
| | Bone and Bones | 3 | 2009 | 317 | 0.100 |
Why?
| | Healthy Volunteers | 1 | 2014 | 219 | 0.100 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 122 | 0.100 |
Why?
| | Aged | 12 | 2025 | 26153 | 0.090 |
Why?
| | Carbon Radioisotopes | 1 | 2011 | 29 | 0.090 |
Why?
| | Adult | 13 | 2024 | 40777 | 0.090 |
Why?
| | Swine | 6 | 2003 | 825 | 0.080 |
Why?
| | Hemodynamics | 1 | 1996 | 1118 | 0.080 |
Why?
| | Organ Specificity | 2 | 2019 | 309 | 0.080 |
Why?
| | Lymph Nodes | 2 | 2003 | 503 | 0.080 |
Why?
| | Neoplasm Metastasis | 2 | 2004 | 688 | 0.080 |
Why?
| | Time Factors | 2 | 2014 | 7123 | 0.080 |
Why?
| | Thyroid Gland | 2 | 2016 | 89 | 0.080 |
Why?
| | Prostate-Specific Antigen | 3 | 2022 | 161 | 0.080 |
Why?
| | Mice, Nude | 1 | 2012 | 679 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 881 | 0.080 |
Why?
| | Gadolinium | 4 | 2002 | 84 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2007 | 3413 | 0.080 |
Why?
| | K562 Cells | 1 | 2009 | 92 | 0.080 |
Why?
| | Blotting, Western | 1 | 2012 | 1179 | 0.070 |
Why?
| | Metabolic Clearance Rate | 1 | 2008 | 115 | 0.070 |
Why?
| | Glioblastoma | 1 | 2012 | 353 | 0.070 |
Why?
| | Parathyroid Neoplasms | 2 | 1997 | 12 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2007 | 5983 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3922 | 0.060 |
Why?
| | Octreotide | 2 | 1999 | 23 | 0.060 |
Why?
| | Adenoma | 3 | 1998 | 218 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2002 | 1471 | 0.060 |
Why?
| | Injections, Intravenous | 2 | 2003 | 197 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 2214 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 381 | 0.060 |
Why?
| | Glutamate Carboxypeptidase II | 1 | 2025 | 8 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1300 | 0.060 |
Why?
| | Molecular Probe Techniques | 1 | 2005 | 8 | 0.060 |
Why?
| | Miniaturization | 1 | 2005 | 22 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2025 | 155 | 0.060 |
Why?
| | X-Ray Microtomography | 1 | 2025 | 108 | 0.060 |
Why?
| | Molecular Biology | 1 | 2005 | 58 | 0.050 |
Why?
| | Equipment Failure Analysis | 1 | 2005 | 124 | 0.050 |
Why?
| | Iodides | 1 | 2004 | 11 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 58 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2016 | 17291 | 0.050 |
Why?
| | Theophylline | 1 | 2004 | 41 | 0.050 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2004 | 73 | 0.050 |
Why?
| | Models, Animal | 2 | 2003 | 393 | 0.050 |
Why?
| | Rats, Wistar | 1 | 2025 | 450 | 0.050 |
Why?
| | Thyroglobulin | 1 | 2004 | 29 | 0.050 |
Why?
| | Biomarkers, Tumor | 2 | 2023 | 1321 | 0.050 |
Why?
| | Equipment Design | 1 | 2005 | 525 | 0.050 |
Why?
| | Neck | 1 | 2003 | 108 | 0.050 |
Why?
| | Artifacts | 1 | 2004 | 143 | 0.050 |
Why?
| | Metanephrine | 1 | 2023 | 4 | 0.050 |
Why?
| | Inhalation | 1 | 2003 | 29 | 0.050 |
Why?
| | Exhalation | 1 | 2003 | 29 | 0.050 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2022 | 6 | 0.050 |
Why?
| | Chromogranin A | 1 | 2023 | 43 | 0.050 |
Why?
| | Gadolinium DTPA | 1 | 2002 | 70 | 0.050 |
Why?
| | Dipeptides | 1 | 2022 | 56 | 0.050 |
Why?
| | Prospective Studies | 3 | 2025 | 8057 | 0.050 |
Why?
| | Movement | 1 | 2004 | 293 | 0.040 |
Why?
| | Intestines | 1 | 2004 | 354 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1067 | 0.040 |
Why?
| | Myocardial Ischemia | 1 | 2002 | 285 | 0.040 |
Why?
| | Aged, 80 and over | 4 | 2015 | 8333 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2006 | 1061 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1368 | 0.040 |
Why?
| | Radioimmunodetection | 1 | 1999 | 2 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2003 | 1132 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2007 | 3124 | 0.040 |
Why?
| | Organotechnetium Compounds | 1 | 1998 | 12 | 0.040 |
Why?
| | Cell Movement | 1 | 2003 | 959 | 0.040 |
Why?
| | Esophageal Neoplasms | 1 | 2003 | 348 | 0.040 |
Why?
| | Bone Neoplasms | 2 | 1999 | 259 | 0.040 |
Why?
| | Pleural Neoplasms | 1 | 1999 | 30 | 0.040 |
Why?
| | Optical Imaging | 1 | 2019 | 61 | 0.040 |
Why?
| | Salvage Therapy | 1 | 1999 | 165 | 0.040 |
Why?
| | Gardner Syndrome | 1 | 1998 | 2 | 0.030 |
Why?
| | Mediastinal Neoplasms | 1 | 1999 | 53 | 0.030 |
Why?
| | Osteoma | 1 | 1998 | 2 | 0.030 |
Why?
| | Gold | 1 | 2019 | 116 | 0.030 |
Why?
| | Retroperitoneal Space | 1 | 1997 | 18 | 0.030 |
Why?
| | Carcinoid Tumor | 1 | 1997 | 21 | 0.030 |
Why?
| | Pilot Projects | 1 | 2003 | 1891 | 0.030 |
Why?
| | Cardiac Volume | 1 | 1997 | 14 | 0.030 |
Why?
| | Duodenal Neoplasms | 1 | 1997 | 26 | 0.030 |
Why?
| | Cysteine | 1 | 1998 | 211 | 0.030 |
Why?
| | HIV-1 | 1 | 2003 | 908 | 0.030 |
Why?
| | Ventricular Function | 1 | 1997 | 53 | 0.030 |
Why?
| | Choristoma | 1 | 1996 | 20 | 0.030 |
Why?
| | Rats | 1 | 2025 | 5584 | 0.030 |
Why?
| | Kidney | 1 | 2024 | 1497 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2019 | 741 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 1999 | 241 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2007 | 4560 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2024 | 1244 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 289 | 0.030 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 1997 | 214 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 81 | 0.030 |
Why?
| | Thoracic Neoplasms | 1 | 1995 | 39 | 0.030 |
Why?
| | Deoxyglucose | 1 | 1995 | 51 | 0.030 |
Why?
| | Radiography | 2 | 2015 | 852 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1374 | 0.030 |
Why?
| | Kallikreins | 1 | 2015 | 26 | 0.030 |
Why?
| | Abiraterone Acetate | 1 | 2015 | 15 | 0.030 |
Why?
| | Colorectal Neoplasms | 1 | 2003 | 866 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1508 | 0.030 |
Why?
| | Lung | 2 | 1999 | 4106 | 0.030 |
Why?
| | Benzamides | 1 | 2015 | 226 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 207 | 0.020 |
Why?
| | Infusions, Intra-Arterial | 1 | 1993 | 61 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 1993 | 26 | 0.020 |
Why?
| | Exercise Test | 1 | 1996 | 630 | 0.020 |
Why?
| | Hepatic Artery | 1 | 1993 | 53 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2015 | 767 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 1999 | 5423 | 0.020 |
Why?
| | Risk Factors | 3 | 2015 | 10885 | 0.020 |
Why?
| | Biopsy | 1 | 2016 | 1082 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 1999 | 1505 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 1996 | 558 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 969 | 0.020 |
Why?
| | Erythrocytes | 1 | 1997 | 748 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 11772 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1327 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 4316 | 0.020 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1999 | 1189 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2865 | 0.020 |
Why?
| | Case-Control Studies | 1 | 1996 | 3623 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2923 | 0.020 |
Why?
| | HIV Infections | 1 | 2003 | 3193 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 14218 | 0.020 |
Why?
| | Brain | 1 | 1999 | 2947 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2864 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 3747 | 0.010 |
Why?
| | Subtraction Technique | 1 | 2004 | 26 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2004 | 207 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2004 | 47 | 0.010 |
Why?
| | Adolescent | 2 | 2018 | 22529 | 0.010 |
Why?
| | HIV Seropositivity | 1 | 2003 | 119 | 0.010 |
Why?
| | Diagnostic Errors | 1 | 2004 | 178 | 0.010 |
Why?
| | Viremia | 1 | 2003 | 160 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 977 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2002 | 196 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 246 | 0.010 |
Why?
| | Virus Replication | 1 | 2003 | 521 | 0.010 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2000 | 156 | 0.010 |
Why?
| | Prostatectomy | 1 | 1999 | 94 | 0.010 |
Why?
| | Vasodilation | 1 | 2002 | 521 | 0.010 |
Why?
| | Influenza Vaccines | 1 | 2003 | 534 | 0.010 |
Why?
| | Intestinal Mucosa | 1 | 2004 | 675 | 0.010 |
Why?
| | Zollinger-Ellison Syndrome | 1 | 1997 | 2 | 0.010 |
Why?
| | Gastrins | 1 | 1997 | 8 | 0.010 |
Why?
| | Radionuclide Angiography | 1 | 1997 | 3 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4148 | 0.010 |
Why?
| | Research Design | 1 | 2002 | 1137 | 0.010 |
Why?
| | Esophagus | 1 | 1996 | 262 | 0.010 |
Why?
| | Heart Diseases | 1 | 1997 | 341 | 0.010 |
Why?
| | Technetium | 1 | 1993 | 10 | 0.010 |
Why?
| | Microspheres | 1 | 1993 | 142 | 0.010 |
Why?
| | Liver | 1 | 1993 | 1896 | 0.000 |
Why?
|
|
Chin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|